ADPKD Clinical Trial
Official title:
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A mild reduction in food intake significantly inhibits renal cyst growth in mouse models of ADPKD. The underlying mechanism was unknown at the time. Recently published data show that the beneficial effect is not due to caloric restriction per se but due to the induction of the state of ketosis. Dietary interventions leading to ketosis profoundly inhibited renal cyst growth in rodent models of PKD. In addition, acute fasting led to rapid regression of renal cystic burden in mouse, rat and feline models of PKD. Due to these compelling effects in a multitude of PKD animal models, and due to the fact that well-established dietary interventions have a tremendous translational potential, KETO-ADPKD will test such interventions regimens in ADPKD patients. Two well-established ketogenic dietary regimens will be tested in comparison to a control group to address the following four questions: 1. Feasibility: Are ketogenic dietary interventions acceptable to ADPKD patients in everyday life? 2. Safety: Are there adverse events of ketogenic dietary interventions in ADPKD patients? 3. Efficacy: Do the dietary interventions reach the metabolic endpoints? Do they have a short-term impact on kidney volume? 4. Which of the two diets is the optimal approach? These questions will be addressed in an exploratory, randomized, open, single center, three-arm dietary intervention study using the following interventions in 21 ADPKD patients per treatment arm: A) Ketogenic diet B) 3-day water fasting C) Control: ad libitum food intake (no diet)
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
| Completed |
NCT02776241 -
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
| Terminated |
NCT04152837 -
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT03717883 -
ADPKD Alterations in Hepatic Transporter Function
|
||
| Recruiting |
NCT05014178 -
Kidney Sodium Functional Imaging
|
||
| Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
| Terminated |
NCT04064346 -
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT03203642 -
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
|
Phase 2 | |
| Recruiting |
NCT04338048 -
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
|
||
| Not yet recruiting |
NCT06100133 -
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
|
Phase 2 | |
| Completed |
NCT01632605 -
The Vienna RAP Pilot Study
|
N/A | |
| Terminated |
NCT03918447 -
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
|
Phase 3 | |
| Recruiting |
NCT06416761 -
Genetics in the Progression of Nephropathies
|
||
| Not yet recruiting |
NCT05373264 -
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
|
Phase 3 | |
| Recruiting |
NCT06085807 -
Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
|
||
| Completed |
NCT01853553 -
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
| Completed |
NCT04472624 -
Short Term Induction of Ketosis in PKD
|
N/A | |
| Not yet recruiting |
NCT03764605 -
Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT02161068 -
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
|
||
| Active, not recruiting |
NCT03273413 -
Statin Therapy in Patients With Early Stage ADPKD
|
Phase 4 |